News | News By Subject | News by Disease News By Date | Search News

Migraine News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AstraZeneca PLC (AZN) Eases Its Migraine With $302 Million Sale     6/7/2017
Allergan (AGN) R&D Chief: Company Forges Ahead With Migraine Treatments     5/3/2017
Allergan (AGN) Looks to Expand Beyond Botox with Oral Migraine Treatments     10/12/2016
Cambridge's CoLucid Pharma (CLCD) Rockets on Late-Stage Migraine Data     9/7/2016
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma     6/9/2016
Alder Biopharma's Migraine Drug Meets Primary and Secondary Endpoints in Phase 2b Trial     3/28/2016
Tonix Pharma (TNXP) Craters as Headache Drug Flunks Phase II Study     2/16/2016
FDA Approves AVANIR (AVNR) New Migraine Treatment With Unique Inhalant Delivery System     2/1/2016
Heptares Lines Up a $410 Million Migraine Pact with Teva (TEVA)     11/25/2015
Allergan (AGN) Slams Down $250 Million+ for Rights to Merck & Co. (MRK)'s Migraine Drugs     7/7/2015
Amgen (AMGN)'s Migraine Drug Meets Goals in Phase II Study     5/19/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
AVANIR Pharmaceuticals (AVNR)'s Migraine Treatment Will Unlikely Win Approval By Scheduled Timeline     11/7/2014
AVANIR Pharmaceuticals (AVNR)' Migraine Drug AVP-825 Meets Primary Endpoint in Phase 3 Trial     6/10/2014

News from Around the Web
There’s A Race To Treat A Condition That Affects 38 Million Americans—Here’s What You Need To Know     6/13/2017
How This Small Washington Biotech Stands To Outperform Rivals Amgen (AMGN), Eli Lilly (LLY) And Teva (TEVA) In Migraine Drugs     6/9/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters     2/14/2017
Amgen (AMGN) Maintains Migraine Drug Lead     9/30/2016
The Drug Industry Might Finally Have An Answer For Migraines     9/26/2016
Does Eating More Salt Prevent Migraines And Severe Headaches? Huntington Medical Research Institutes Study     8/16/2016
Emotional Abuse In Childhood Linked To Migraines In Adulthood, Yale University Study     7/14/2016
NYU Langone Medical Center Researchers Pinpoint Best Meds To Treat Migraine In The ED     6/27/2016
Can Light Help Ease The Pain Of Migraines? Texas A&M University Study     6/23/2016
Migraines Linked To Vitamin Deficiencies, Cincinnati Children's Hospital Medical Center Says Study     6/13/2016
New Drug To Prevent Migraine May Start Working In Days, Teva (TEVA) Reveals     6/9/2016
Women With Migraines More Prone To Heart Disease And Early Death, Harvard Medical School Study     6/1/2016
Green Light For Migraine Relief, Harvard Medical School Study     5/20/2016
Botox Can Be Used For Chronic Migraine, Icahn School Of Medicine At Mount Sinai Study     4/21/2016
An App A Day To Keep The Doctor Away     3/28/2016

Press Releases
touchNEUROLOGY Release: New Review Provides An Overview Of Triptans In The Treatment Of Acute Migraine     9/19/2017
IHC 2017: Eli Lilly (LLY)'s Lasmiditan Significantly Reduces Pain In Patients With Migraine     9/11/2017
electroCore Announces Results From gammaCore (Non-Invasive Vagus Nerve Stimulator) Study In Migraine At The 18th Congress Of The International Headache Society     9/11/2017
Teva (TEVA) Showcases Data Demonstrating Potential Of Fremanezumab To Address Significant Unmet Need In Patients With Chronic And Episodic Migraine     9/11/2017
Amgen (AMGN) Release: New Data Demonstrate Aimovig (Erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies     9/8/2017
Novartis AG (NVS) Presents New Analysis Demonstrating AMG 334 (Erenumab) Significantly Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies     9/8/2017
Alder Biopharma (ALDR)To Present Data From Eptinezumab Development Program At 18th Congress Of The International Headache Society     9/7/2017
FDA Green Lights eNeura's Use of SpringTMS for Migraine Prevention     9/7/2017
BioElectronics Corporation Announces Update On Migraine Clinical Study Migraine Prevention Using Actipatch (Neuromodulation Therapy)     8/10/2017
Primary Endpoint Met in Eli Lilly (LLY)'s Phase III Trial for Migraine Drug Lasmiditan     8/4/2017
Biohaven (BHVN) Initiates Second Pivotal Phase III Clinical Trial Of Oral CGRP Antagonist For The Acute Treatment Of Migraine     7/31/2017
Imaging Study Expands Upon Previous Findings That Cefaly Device Is Effective In Blocking Migraine Pain     7/25/2017
Biohaven (BHVN) Enrolls First Patient In Pivotal Phase III Clinical Trial Of Oral Rimegepant For The Acute Treatment Of Migraine     7/24/2017
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab)     7/21/2017
FDA Accepts Biologics License Application For AMG 334 (Erenumab), An Important Regulatory Milestone For Novartis AG (NVS)     7/21/2017

//-->